參考文獻(xiàn)/References:
[1] 張荒生,陳麗川,王進(jìn)軍,等.痹痛定分散片對大鼠AA模型血清TGF-β1及滑膜組織病理形態(tài)學(xué)的影響[J].光明中醫(yī),2009,24(4):648-651.
[2] 王婷,張金超.抗骨質(zhì)疏松癥的單味中藥及藥用植物研究進(jìn)展[J].中國中藥雜志,2006,31(5):719-722.
[3] 陳順,關(guān)延彬.骨碎補(bǔ)藥理作用的研究進(jìn)展[J].醫(yī)藥導(dǎo)報(bào),2006,25(7):685.
[4] 昝強(qiáng),朱超,屈強(qiáng),等.強(qiáng)骨湯治療腎虛型骨質(zhì)疏松癥56例[J].陜西中醫(yī),2006,27(8):957-959.
[5] 黃永明,許少健,石宇雄,等.骨松安膠囊治療絕經(jīng)后骨質(zhì)疏松癥34例[J].陜西中醫(yī),2006,27(8):954-956.
[6] 周軍杰,曹成福,紀(jì)斌,等.丹黃補(bǔ)骨方調(diào)控骨形成功能的療效特征[J].中國臨床康復(fù),2006,10(31):37-40.
[7] 柳景紅.抗骨衰丸對原發(fā)性骨質(zhì)疏松癥患者臨床證候及相關(guān)實(shí)驗(yàn)室指標(biāo)的干預(yù)[J].中國臨床康復(fù),2006,10(23):13-17.
[8] 王和鳴,葛繼榮,田金洲,等.強(qiáng)骨膠囊治療原發(fā)性骨質(zhì)疏松癥臨床試驗(yàn)[J].中藥新藥與臨床藥理,2004,15(4):284-287.
[9] 張勇軍.骨碎補(bǔ)總黃酮對去卵巢大鼠OPG和血清TRACP表達(dá)的影響[J].中南大學(xué),2009,10(1):13-18.
[10] Mandelin J,Li TF,LiljeströmM,et al.Imbalance of RANKL/RANK/OPG system in interface tissue in loosening of total hip replacement[J].J Bone Joint Surg Br, 2003,85(8):1196-1201.
[11] Adachi JD,Saag KG,DelmasPD,et al.Two-year effects of alen-dronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids:a randomized,double-blind,placebo-controlled extension trial[J].Arthritis Rheum 2001,44(1):202-211.
[12] Hofbauer LC,Heufelder AE.The role of receptor activator of nuclear factor-kappa B ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases[J].J Clin Endocrinol Metab,2000,85(7):2355-2363.
[13] Burgess TL,Qian Y,Kaufman S,et al.The ligand for osteoprotegerin(OPGL)directly activates mature osteoclasts[J].J Cell Biol,1999,145(3):527-538.
[14] Wei S,Wang MW,Teitelbaum SL,et al.Interleukin-4 reversibly inhibits osteoclastogenesis via inhibition of NF-kappa B and mitogen-activated protein kinase signaling[J].J Biol Chem,2002,277(8):6622-6630.
[15] Karsdal MA,Hjorth P,Henrisken K,et al.Transforming growth factor-beta controls human osteoclastogenesis through the p38 MAPK and regulation of RANK expression[J].J Biol Chem,2003,278(45):44975-44987.
[16] Kostenuik PJ,Bolon B,Morony S,et al.Gene therapy with human recombinant osteoprotegerin reverses established osteopenia in ovariectomized mice[J].Bone,2004,34(4):656-664.
[17] Hofbauer LC,Khosla S,Dunstan CR,et al.The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption[J].J Bone Miner Res,2000,15(1):2-12.
[18] Bekker PJ,Holloway D,Nakanishi A,et al.The effect of a single dose of osteoproteger in postmenopausal women[J].J Bone Miner Res,2001,16(2):348-360.
[19] 廖悅?cè)A,梁瓊,王卓,等.中藥骨碎補(bǔ)對去睪丸骨質(zhì)疏松癥動(dòng)物模型的影響[J].中國骨質(zhì)疏松雜志,2007,13(4):277-280.
[20] 謝雁鳴,趙晉寧,丁會,等.強(qiáng)骨膠囊抗去勢大鼠骨質(zhì)疏松癥的實(shí)驗(yàn)研究[J].中國中醫(yī)藥科技,2000,7(3):151-152.
[21] 黃秀蘭,周亞偉,王偉.淫羊藿黃酮類化合物藥理研究進(jìn)展[J].中成藥,2005,27(6):719-721.
[22] 宋麗華,肖洲生,周宏灝.植物性雌激素的研究進(jìn)展[J].國外醫(yī)學(xué):藥學(xué)分冊,2003,30(1):25-29.
[23] Nifli AP,Bosson-Kouamé A,Papadopoulou N,et al.Monomeric and oligomeric flavanols are agonists of membrane and rogen receptors[J].Exp Cell Res,2005,309(2):329-339.